Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Employees - 10, CEO - Dr. Neil Maresky M.D., Sector - Healthcare, Country - CA, Market Cap - 3.48M

Altman ZScore(max is 10): -7157.31, Piotroski Score(max is 10): 2, Working Capital: $-10977, Total Assets: $1132, Retained Earnings: $-57458, EBIT: -2472851, Total Liabilities: $12104, Revenue: $0

AryaFin Target Price - $-1.04 - Current Price $3.18 - Analyst Target Price $-